Skip to main content
Health & Wellness

Daraxonrasib Pancreatic Cancer Trial: What It Found

Daraxonrasib pancreatic cancer trial explained: what the phase 3 study found on survival and side effects, why RAS was undruggable, and who can get it now.

Priya Raman
November 22, 202610 min read
Share
Daraxonrasib Pancreatic Cancer Trial: What It Found
Table of contents

You see the headline on your phone: a pill that makes pancreatic cancer disappear. If someone you love has this cancer, your next thought is probably "can they get it, and will it work for them?" The headline comes from a daraxonrasib pancreatic cancer trial, and the trial is real. It is also more specific, and more modest, than the word "disappear" suggests.

This guide walks through what the phase 3 trial measured, what the survival numbers mean in plain terms, why scientists spent four decades calling this target "undruggable," and what a patient can actually do with this news right now.

What the Daraxonrasib Pancreatic Cancer Trial Actually Tested

The study is called RASolute 302. It was a phase 3 trial, the large, randomized stage that regulators rely on to approve a drug. The results were presented at the American Society of Clinical Oncology meeting on May 31 and published the same day in the New England Journal of Medicine.

Here is who was in it and what they got:

  • 500 adults with metastatic pancreatic ductal adenocarcinoma, the most common type, across North America, Europe and Asia.
  • Everyone had already been treated with at least one round of chemotherapy, and their cancer had kept growing.
  • 248 people were randomly assigned to take daraxonrasib, an oral pill. 252 got chemotherapy chosen by their doctor.
  • About 92% of patients carried a RAS G12 mutation, the most common kind in this cancer.

The trial was open-label, meaning patients and doctors knew which treatment each person received. That matters more for soft measures like quality of life than for survival.

The trial had two "primary endpoints," the outcomes it was designed to prove. One was overall survival, how long people lived. The other was progression-free survival, how long before the cancer grew or spread.

The Survival Numbers, Explained Without the Hype

According to the New England Journal of Medicine paper, the results looked like this:

  • Overall survival: a median of 13.2 months on daraxonrasib versus 6.7 months on chemotherapy across all patients (6.6 months in the RAS G12 group). The hazard ratio was 0.40 in both groups.
  • Progression-free survival: 7.2 months versus 3.6 months overall.
  • Tumor response: 31.6% of patients on daraxonrasib had their tumors shrink substantially, versus 11.2% on chemotherapy.

A worked example: what these numbers mean for 100 patients

Picture 100 people starting daraxonrasib and 100 starting chemotherapy. A median is the midpoint. So in the chemotherapy group, half of the people would still be alive at about 6.7 months. In the daraxonrasib group, half would still be alive at about 13.2 months.

That is roughly six and a half extra months at the midpoint. The hazard ratio of 0.40 means that at any given point during the study, a person on daraxonrasib had about 60% lower risk of dying than a comparable person on chemotherapy.

Now look at shrinkage. About 32 of the 100 on daraxonrasib would see a substantial response, against about 11 of the 100 on chemotherapy. The other two thirds on the new drug would not. And at a median of about 7 months, half of the daraxonrasib group would see their cancer start growing again.

That is why "disappear" overstates it. A response in a trial means a tumor shrank by a set amount on scans. Specialists at Memorial Sloan Kettering have stressed that the drug is not a cure. It buys time for many patients, and for some it buys a lot.

Why doubling survival still counts as a big deal

Context makes the result land. The National Cancer Institute's SEER program estimates 67,530 new pancreatic cancer cases and 52,740 deaths in the United States this year. For cancer that has already spread, the five-year relative survival rate is 3.4%.

Second-line chemotherapy has offered little. Six or seven months was the expected median. A pill that roughly doubles that, in people whose first treatment already failed, is why Dr. Eileen O'Reilly of Memorial Sloan Kettering called it "a sea change, but we are just at the beginning."

Why RAS Was Called "Undruggable" for Four Decades

RAS is a family of proteins that act like an on/off switch for cell growth. When a RAS gene mutates, the switch can get stuck in the "on" position, telling the cell to keep dividing. The National Cancer Institute says RAS mutations help drive roughly a third of all cancers, including more than 90% of pancreatic cancers.

Scientists found these mutations in the late 1970s and early 1980s. Turning that knowledge into a drug proved brutally hard, for two main reasons:

  • No place to grab. As the NCI puts it, RAS proteins have relatively smooth surfaces, with no obvious place for a drug molecule to bind. Most drugs work by slotting into a pocket on a protein.
  • The fuel binds too tightly. RAS switches on by binding a molecule called GTP. It holds GTP so tightly, and cells contain so much of it, that blocking that site with a look-alike molecule was judged unworkable.

The NCI launched its RAS Initiative in 2013 specifically to attack this problem. The first crack came in May 2021, when the FDA approved sotorasib for lung cancers with one specific mutation, KRAS G12C.

What makes daraxonrasib different

Sotorasib and similar drugs target a single mutation. That helps in lung cancer, but G12C is rare in pancreatic cancer, where a different mutation, G12D, dominates. The NCI's Frederick National Laboratory notes that single-mutation drugs also tend to run into resistance.

Daraxonrasib takes a broader approach. It is a "multi-selective RAS(ON)" inhibitor. Instead of hunting one mutation, it latches onto RAS in its active, switched-on state. It does this by recruiting a helper protein in the cell called cyclophilin A, forming a three-part complex that blocks RAS from passing its growth signal along. Dana-Farber describes this as a molecular glue. Because it targets the active form, it works against many RAS variants, and the trial found benefit even in patients with no RAS mutation identified.

Side Effects: What Patients in the Trial Reported

No cancer drug is free of side effects, and this one has a distinct profile. The FDA lists the most common as rash, diarrhea, and mouth sores (stomatitis), along with nausea, fatigue, vomiting, abdominal pain, swelling, decreased appetite and bleeding.

Memorial Sloan Kettering says the rash can be inflamed and sore, and care teams manage it with creams and, when needed, dermatology support.

Here is how the two arms compared in the published paper:

  • Serious side effects (grade 3 or higher): 61.8% on daraxonrasib versus 69.6% on chemotherapy.
  • Stopping treatment because of side effects: 1.2% versus 11.2%. That is roughly 1 in 83 people versus about 1 in 9.

The American Cancer Society also reports that patients on daraxonrasib went about twice as long before reporting worsening pain or quality of life. Any changes to how much or how often you take it should come only from your oncology team.

Who Can Get Daraxonrasib Now

The FDA approved daraxonrasib under the brand name Rasonque on August 26. The approval covers adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy, or who are not candidates for multi-drug chemotherapy. The FDA said the decision came 6.5 months before its deadline.

Outside the US, the picture is still moving:

  • Europe: On October 15, the European Medicines Agency's human medicines committee recommended authorisation. The European Commission makes the final call, and each country then sets price and reimbursement.
  • India and elsewhere: Availability outside the US and Europe varies, so ask your oncologist whether it is approved or obtainable where you live. Access there depends on local approval, clinical trials, or special import routes your oncologist would need to arrange.

Price has not been widely reported. In the US, ask your insurer early about prior authorization. Our guide to lowering what you pay for health insurance covers how plan choices affect specialty drug costs.

If the cancer has not been treated yet

The approval does not cover people starting treatment for the first time. That question is being tested in a separate phase 3 trial, RASolute 303, which compares daraxonrasib alone or with chemotherapy against chemotherapy alone. Another phase 3 trial is testing it after surgery to see whether it can stop the cancer from returning. Joining one of these trials is the main route to the drug in those settings.

What to Ask Your Oncologist This Week

If you or a family member has pancreatic cancer, bring these questions to the next appointment:

  1. Has the tumor had genetic testing? RAS status, and other mutations, can shape treatment choices and trial eligibility.
  2. Am I eligible for daraxonrasib now, based on my stage and earlier treatments?
  3. Is there a trial that fits me if I am newly diagnosed or recently had surgery?
  4. How will we manage side effects like rash and mouth sores, and who do I call if they flare?
  5. What does coverage look like under my insurance or in my country?

Our explainer on what a failed heart drug trial teaches about endpoints shows the other side: how a promising drug can miss its main goal. And if cancer screening is on your mind for other reasons, see our guide to the latest PSA screening advice.

Frequently Asked Questions

Does daraxonrasib cure pancreatic cancer?

No. In the phase 3 trial it roughly doubled median survival, from 6.7 to 13.2 months, and shrank tumors substantially in about a third of patients. Specialists stress it is not a cure, and most patients' cancer eventually grew again.

Is daraxonrasib FDA approved?

Yes. The FDA approved it as Rasonque on August 26 for adults with metastatic pancreatic adenocarcinoma who already had at least one prior systemic therapy or cannot take multi-drug chemotherapy. It is not approved as a first treatment.

What are the side effects of daraxonrasib?

The most common are rash, diarrhea and mouth sores, plus nausea, fatigue and vomiting. In the trial, 1.2% of patients stopped the drug because of side effects, compared with 11.2% on chemotherapy.

Why was RAS called undruggable?

RAS proteins have smooth surfaces with no obvious pocket for a drug to bind, and they hold their activating molecule, GTP, extremely tightly. Daraxonrasib gets around this by gluing onto active RAS with a helper protein in the cell.

Can patients in India get daraxonrasib?

Outside the US and Europe, ask your oncologist whether it is approved or obtainable where you live. Patients should ask their oncologist about clinical trials or any legal import route, and never buy cancer drugs from unverified online sellers.

The Bottom Line on Daraxonrasib

Daraxonrasib is the first drug to hit RAS broadly in pancreatic cancer, and the phase 3 trial shows it doubled median survival in previously treated patients with fewer people quitting because of side effects. That is real progress in one of the hardest cancers to treat.

It is not a vanishing act, and it is not yet a first-line option. The next big answers will come from the first-line and post-surgery trials. Until then, the most useful step is a conversation with an oncologist who knows the full case, including tumor testing, eligibility and trial options.

Share

Written by

Priya Raman

Health & Living

Covers health, wellness, and everyday living for Quick Trend Insights, with an interest in separating what the research supports from what the marketing claims.

More articles

Related Articles

View all